JP6415535B2 - フロセミドの皮下投与用の医薬製剤 - Google Patents

フロセミドの皮下投与用の医薬製剤 Download PDF

Info

Publication number
JP6415535B2
JP6415535B2 JP2016506607A JP2016506607A JP6415535B2 JP 6415535 B2 JP6415535 B2 JP 6415535B2 JP 2016506607 A JP2016506607 A JP 2016506607A JP 2016506607 A JP2016506607 A JP 2016506607A JP 6415535 B2 JP6415535 B2 JP 6415535B2
Authority
JP
Japan
Prior art keywords
furosemide
tris
pharmaceutical formulation
liquid pharmaceutical
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016506607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515623A (ja
JP2016515623A5 (enExample
Inventor
マイケルズ，スコット，エー．
ムンテンダム，ピーター
ラーセン，グレン，アール．
Original Assignee
エスシーファーマシューティカルズ インコーポレイテッド
エスシーファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスシーファーマシューティカルズ インコーポレイテッド, エスシーファーマシューティカルズ インコーポレイテッド filed Critical エスシーファーマシューティカルズ インコーポレイテッド
Publication of JP2016515623A publication Critical patent/JP2016515623A/ja
Publication of JP2016515623A5 publication Critical patent/JP2016515623A5/ja
Application granted granted Critical
Publication of JP6415535B2 publication Critical patent/JP6415535B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016506607A 2013-04-05 2014-04-03 フロセミドの皮下投与用の医薬製剤 Active JP6415535B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
US61/808,962 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018187299A Division JP6677779B2 (ja) 2013-04-05 2018-10-02 フロセミドの皮下投与用の医薬製剤

Publications (3)

Publication Number Publication Date
JP2016515623A JP2016515623A (ja) 2016-05-30
JP2016515623A5 JP2016515623A5 (enExample) 2017-05-18
JP6415535B2 true JP6415535B2 (ja) 2018-10-31

Family

ID=51659206

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016506607A Active JP6415535B2 (ja) 2013-04-05 2014-04-03 フロセミドの皮下投与用の医薬製剤
JP2018187299A Active JP6677779B2 (ja) 2013-04-05 2018-10-02 フロセミドの皮下投与用の医薬製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018187299A Active JP6677779B2 (ja) 2013-04-05 2018-10-02 フロセミドの皮下投与用の医薬製剤

Country Status (14)

Country Link
US (5) US9884039B2 (enExample)
EP (3) EP2981258B8 (enExample)
JP (2) JP6415535B2 (enExample)
KR (2) KR102266460B1 (enExample)
CN (1) CN105431145B (enExample)
AU (1) AU2014248164B2 (enExample)
CA (1) CA2908935C (enExample)
DK (1) DK2981258T3 (enExample)
ES (1) ES2823589T3 (enExample)
IL (1) IL241917B (enExample)
MX (1) MX367165B (enExample)
PT (1) PT2981258T (enExample)
SG (2) SG11201508251RA (enExample)
WO (1) WO2014165660A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431145B (zh) * 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
DE102014115951A1 (de) * 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) * 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
EP3906020B1 (en) 2019-01-04 2025-12-31 SQ Innovation AG Pharmaceutical compositions of torsemide and their uses
AU2020214314B2 (en) * 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
IL300152A (en) * 2020-08-05 2023-03-01 Scpharmaceuticals Inc Methods of treatment using furosemide
WO2022212813A1 (en) 2021-04-02 2022-10-06 Scpharmaceuticals Inc. Subcutaneous infusion of furosemide
JP2024520788A (ja) * 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) * 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
ES2136090T3 (es) * 1991-05-30 1999-11-16 Abbott Lab Reactivos que contienen un inhibidor de fijacion no especifico para analisis de fijacion con captura de iones.
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
AU4866196A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
PL1803934T3 (pl) 2005-12-28 2009-03-31 Sensile Pat Ag Mikropompa
ES2780193T3 (es) * 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
MX340669B (es) * 2008-09-09 2016-07-20 Cima Labs Inc Formas farmaceuticas para compuestos debilmente ionizables.
MX2012002762A (es) * 2009-09-04 2012-06-12 Minipumps Llc Parche cutaneo adhesivo con bomba para suministro subcutaneo de farmacos.
CN103998047A (zh) 2011-10-19 2014-08-20 墨卡托医疗系统公司 局部调节组织和细胞以提高疗效包括肾去神经支配
CN105431145B (zh) 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) * 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
AU2020214314B2 (en) * 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US12042709B1 (en) * 2022-02-22 2024-07-23 Craig E. Williams Fighting training device

Also Published As

Publication number Publication date
US20160051507A1 (en) 2016-02-25
US20250339397A1 (en) 2025-11-06
JP2016515623A (ja) 2016-05-30
KR20210075211A (ko) 2021-06-22
EP3799869A1 (en) 2021-04-07
MX2015014064A (es) 2017-04-13
US20230201156A1 (en) 2023-06-29
EP2981258B1 (en) 2020-08-12
EP4696308A1 (en) 2026-02-18
ES2823589T3 (es) 2021-05-07
CN105431145B (zh) 2019-12-10
KR102493735B1 (ko) 2023-01-30
US10272064B2 (en) 2019-04-30
JP6677779B2 (ja) 2020-04-08
BR112015025204A2 (pt) 2021-03-16
US20180303790A1 (en) 2018-10-25
KR102266460B1 (ko) 2021-06-17
MX367165B (es) 2019-08-07
CN105431145A (zh) 2016-03-23
CA2908935C (en) 2021-06-15
US11433044B2 (en) 2022-09-06
US12370168B2 (en) 2025-07-29
HK1221152A1 (zh) 2017-05-26
SG10201709388QA (en) 2017-12-28
US20200038364A1 (en) 2020-02-06
CA2908935A1 (en) 2014-10-09
EP2981258A1 (en) 2016-02-10
AU2014248164B2 (en) 2019-05-23
KR20160014592A (ko) 2016-02-11
EP2981258A4 (en) 2016-10-05
DK2981258T3 (da) 2020-10-19
EP3799869B1 (en) 2025-08-27
EP2981258B8 (en) 2020-11-11
AU2014248164A1 (en) 2015-10-15
PT2981258T (pt) 2020-10-19
WO2014165660A1 (en) 2014-10-09
IL241917B (en) 2020-10-29
JP2019001821A (ja) 2019-01-10
US9884039B2 (en) 2018-02-06
SG11201508251RA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
JP6677779B2 (ja) フロセミドの皮下投与用の医薬製剤
TWI674899B (zh) 醫藥配方
KR102923666B1 (ko) 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법
US20200338082A1 (en) Formulations, systems, and methods for therapeutic treatment
CN105566100A (zh) 一种苯乙烯酸类化合物，包含其的组合物及其应用
HK40049405A (en) Pharmaceutical formulations for subcutaneous administration of furosemide
HK40049405B (en) Pharmaceutical formulations for subcutaneous administration of furosemide
HK1221152B (en) Pharmaceutical formulations for subcutaneous administration of furosemide
JP2002080361A (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
BR112015025204B1 (pt) Formulação farmacêutica líquida de furosemida e seu uso
EA046008B1 (ru) Концентрированные жидкие фармацевтические составы фуросемида и способы их введения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180828

R155 Notification before disposition of declining of application

Free format text: JAPANESE INTERMEDIATE CODE: R155

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181002

R150 Certificate of patent or registration of utility model

Ref document number: 6415535

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250